Windtree Therapeutics, Inc. (OTCPK: WINT)
Health Care · Biotechnology · US
$0.00
-50.00% today · -99.9% 1Y
Windtree Therapeutics, Inc. (OTCPK: WINT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.50K and employs 14 people.
Over the last twelve months the share price has lost 99.9%, trading between 0.00 and 0.19.
Tweenvest scores Windtree Therapeutics, Inc. across four factors: quality 6/100. Its strongest factor is quality.
WINT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.50K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.90
- Dividend yield
- —
- Beta (5Y)
- 1.62
- 52-week high
- $0.19
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 44.99M
- Employees
- 14
- Next earnings
- —
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
- ISIN
- US97382D6004
- Founded
- 1992
- Listed since
- Aug 7, 1995
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.